Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

Summary In myelodysplastic syndromes (MDS), the 20q deletion [del(20q)] may cause deletion of the ASXL1 gene. We studied 153 patients with MDS and del(20q) to assess the incidence, prognostic value and impact on response to azacitidine (AZA) of ASXL1 chromosomal alterations and genetic mutations. Ad...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2021-08, Vol.194 (4), p.708-717
Hauptverfasser:	Martín, Iván, Villamón, Eva, Abellán, Rosario, Calasanz, Maria José, Irigoyen, Aroa, Sanz, Guillermo, Such, Esperanza, Mora, Elvira, Gutiérrez, Míriam, Collado, Rosa, García‐Serra, Rocío, Vara, Míriam, Blanco, Mª Laura, Oiartzabal, Itziar, Álvarez, Sara, Bernal, Teresa, Granada, Isabel, Xicoy, Blanca, Jerez, Andrés, Calabuig, Marisa, Diez, Rosana, Gil, Ángela, Díez-Campelo, María, Solano, Carlos, Tormo, Mar
Format:	Artikel
Sprache:	eng
Schlagworte:	20q deletion Acute myeloid leukemia Aged Aged, 80 and over Antimetabolites, Antineoplastic - therapeutic use ASXL1 azacitidine Azacitidine - therapeutic use Chromosome Deletion Female Gene deletion gene mutations Hematology Humans Incidence Male Middle Aged Mutation Myelodysplastic syndrome myelodysplastic syndromes Myelodysplastic Syndromes - diagnosis Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - genetics p53 Protein Patients Prognosis Repressor Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!